Athena Wong

Athena is Vice President of Cell Therapy Process Development at Sana Biotechnology. Since 2019, she has led process development and MSAT groups focused on allogeneic, genome modified CAR T and pluripotent stem cell (PSC) derived products as well as viral vector producer host cell line engineering. She is also the CMC team leader for Sana’s first allogeneic CAR T program that cleared IND in 2023. Prior to Sana, Athena was at Genentech/Roche for over 12 years in the Cell Culture Department in Pharma Technical Development with a joint appointment in the Antibody Engineering Department in Genentech Research and Early Development (gRED). She led large molecule CMC teams and served as the leader of a global bioprocess platform innovation team for the Roche manufacturing network. Athena earned her PhD in Genetics and Immunology from the University of North Carolina, Chapel Hill and BS in Genetics from UC Davis.